TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Dec 31, 2023. Filed Feb 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 12, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Director and Officer Rule 10b5-1 Trading Arrangements
During the three months ended December 31, 2023, each of the following officers adopted a Rule 10b5-1 trading arrangement (as such term is defined in Item 408 of Regulation S-K). All trading plans are intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
| Name and Title | Date | Action | Expiration Date | Maximum SharesSubject to Plan (1) |
|---|---|---|---|---|
| Richard D. Francis, President and CEO | November 13, 2023 | Adopted | March 6, 2024 | 228,886 |
| Vikki Conway, Acting Head of Global Human Resources | November 21, 2023 | Adopted | March 8, 2024 | 21,544 |
| Richard Daniell, EVP, Head of European Commercial | November 13, 2023 | Adopted | March 8, 2024 | 379,746 |
| Eric Drapé, EVP, Global Operations | November 13, 2023 | Adopted | March 8, 2024 | 341,312 |
| Dr. Eric Hughes, EVP, Global R&D and Chief Medical Officer | November 13, 2023 | Adopted | August 3, 2024 | 77,642 |
| Eli Kalif, EVP, Chief Financial Officer | November 27, 2023 | Adopted | March 8, 2024 | 77,550 |
| (1) | Certain plans include shares to be sold solely to cover tax withholding obligations. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.